Arca
Skip to content
Tools
Tools

Label Changes: Gavreto (pralsetinib)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Gavreto label DailyMed has published, from Rigel Pharmaceuticals, Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 5
  • Sections changed, version 7 to 8: 13, Including the boxed warning

What changed from version 7 to version 8

Dec 19, 2025 to Jan 28, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Boxed warningNew section · 50 words added
  2. Indications and usageChanged · 8 words added, 4 removed
  3. Dosage and administrationChanged · 98 words added, 68 removed
  4. Warnings and precautionsChanged · 129 words added, 9 removed
  5. Adverse reactionsChanged · 179 words added, 46 removed
  6. Drug interactionsChanged · punctuation or symbols only
  7. Use in specific populationsChanged · 8 words added, 4 removed
  8. Clinical pharmacologyChanged · 57 words added, 49 removed
  9. Clinical studiesChanged · 37 words added, 19 removed
  10. Patient counseling informationChanged · 47 words added, 11 removed
  11. Medication guideNew section · 1,517 words added
  12. Patient informationRemoved · 1,371 removed
  13. Untitled sectionChanged · 10 words added, 8 removed

Boxed warning

New section50 words added
WARNING: SERIOUS INFECTIONS, INCLUDING OPPORTUNISTIC INFECTIONS
GAVRETO may increase the risk for serious infections, including bacterial, fungal, viral and opportunistic infections, which can lead to hospitalization or death. Withhold, reduce the dose or permanently discontinue GAVRETO based on severity [see Dosage and Administration (2.3), Warnings and Precautions (5.1)].

Indications and usage

Changed8 words added, 4 removed
1 INDICATIONS AND USAGE
1.1 Metastatic RETFusionRET Fusion-Positive Non-Small Cell Lung Cancer
GAVRETO is indicated for the treatment of adult patients with metastatic RETfusionRET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
1.2 RETFusionRET Fusion-Positive Thyroid Cancer
GAVRETO is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RETfusionRET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14.2)] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Dosage and administration

Changed98 words added, 68 removed
1 unchanged line
2.1 Patient Selection
Select patients for treatment with GAVRETO based on the presence of a RETgeneRET gene fusion (NSCLC or thyroid cancer) [see Clinical Studies (14)] .
Information on FDA-approved tests for RETgeneRET gene fusion (NSCLC) is available at http://www.fda.gov/CompanionDiagnostics.
An FDA-approved test for the detection of RETgeneRET gene fusion (thyroid cancer) is not currently available.
2.2 Recommended Dosage
12 unchanged lines
Table 2: Recommended Dosage Modifications for GAVRETO for Adverse Reactions
Adverse ReactionReactions | Severity | Dosage Modification
ILD/PneumonitisSerious Infections, Including Opportunistic Infections [see Warnings and Precautions (5.1)] | Grade 12 or 23 | Withhold GAVRETO until resolution. Resume byat reducinga thereduced dose as shown in (Table 1).
Permanently discontinue GAVRETO for recurrent ILD/pneumonitis.
Grade 4 | Permanently discontinue GAVRETO.
ILD/Pneumonitis [see Warnings and Precautions (5.2)] | Grade 1 or 2 | Withhold GAVRETO until resolution. Resume by reducing the dose as shown in Table 1. Permanently discontinue GAVRETO for recurrent ILD/pneumonitis.
Grade 3 or 4 | Permanently discontinue for confirmed ILD/pneumonitis.
Grade 4 | Permanently discontinue GAVRETO.
Hypertension [see Warnings and Precautions (5.23)] | Grade 3 | Withhold GAVRETO for Grade 3 hypertension that persists despite optimal antihypertensive therapy. Resume at a reduced dose when hypertension is controlled.
Grade 4 | Discontinue GAVRETO.
Hepatotoxicity [see Warnings and Precautions (5.34)] | Grade 3 or 4 | Withhold GAVRETO and monitor AST/ALT once weekly until resolution to Grade 1 or baseline. Resume at reduced dose (Table 1). For recurrent events at Grade 3 or higher, discontinue GAVRETO.
Resume at reduced dose (Table 1).
For recurrent events at Grade 3 or higher, discontinue GAVRETO.
Hemorrhagic Events [see Warnings and Precautions (5.45)] | Grade 3 or 4 | Withhold GAVRETO until recovery to baseline or Grade 0 or 1. Discontinue GAVRETO for severe or life-threatening hemorrhagic events.
Discontinue GAVRETO for severe or life-threatening hemorrhagic events.
Other Adverse Reactions [see Adverse Reactions (6.1)] | Grade 3 or 4 | Withhold GAVRETO until improvement to ≤ Grade 2. Resume at reduced dose (Table 1). Permanently discontinue for recurrent Grade 4 adverse reactions.
Permanently discontinue for recurrent Grade 4 adverse reactions.
2.4 Dose Modification for Use withCYP3Awith CYP3A and/or P-glycoprotein (P-gp) Inhibitors
Avoid coadministration of GAVRETO with any of the following:
4 unchanged lines
Combined P-gp and moderate CYP3A inhibitors
If coadministration with any of the above inhibitors cannot be avoided, reduce the current dose of GAVRETO as recommended in Table 3. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, resume GAVRETO at the dose taken prior to initiating the inhibitor [see Drug Interactions (7.1), Clinical Pharmacology (12.3)] .
Table 3: Recommended Dosage Modifications for GAVRETO for Coadministration with CYP3A and/or P-gp Inhibitors
8 unchanged lines
Moderate CYP3A inducers
If coadministration with any of the above inducers cannot be avoided, increase the starting dose of GAVRETO as recommended in Table 4 starting on Day 7 of coadministration of GAVRETO with the inducer. After the inducer has been discontinued for at least 14 days, resume GAVRETO at the dose taken prior to initiating the inducer [see Drug Interactions (7.1), Clinical Pharmacology (12.3)] .
Table 4: Recommended Dosage Modifications for GAVRETO for Coadministration with CYP3A Inducers
5 unchanged lines

Warnings and precautions

Changed129 words added, 9 removed
5 WARNINGS AND PRECAUTIONS
5.1 Serious Infections, Including Opportunistic Infections
GAVRETO may increase the risk for serious infections, including fatal and opportunistic infections. In the AcceleRET-Lung trial [see Adverse Reactions (6.1)], infections occurred in 72% of patients who received GAVRETO, including 18% with Grade 3, 3.7% with Grade 4, and 7% with fatal outcomes. Among the patients who received chemotherapy/immunotherapy, infections occurred in 52%, including 10% with Grade 3. Infections in the GAVRETO arm included pneumonia, urinary tract infection, opportunistic infections (such as pneumocystis jirovecii pneumonia, and fungal infections) and others. Monitor patients for signs and symptoms of infection and treat appropriately. Withhold, reduce the dose, or permanently discontinue GAVRETO based on severity [see Dosage and Administration (2.3)].
5.12 Interstitial Lung Disease/Pneumonitis
Severe, life-threatening, and fatal interstitial lung disease (ILD) / pneumonitis can occur in patients treated with GAVRETO. Pneumonitis occurred in 12% of patients who received GAVRETO, including 3.3% with Grade 3-4, and 0.2% with fatal reactions.
Monitor for pulmonary symptoms indicative of ILD/pneumonitis. Withhold GAVRETO and promptly investigate for ILD in any patient who presents with acute or worsening of respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever). Withhold, reduce dose or permanently discontinue GAVRETO based on severity of confirmed ILD [see Dosage and Administration (2.3)] .
5.23 Hypertension
Hypertension occurred in 35% of patients, including Grade 3 hypertension in 18% of patients [see Adverse Reactions (6.1)] . Overall, 8% had their dose interrupted and 4.8% had their dose reduced for hypertension. Treatment-emergent hypertension was most commonly managed with anti-hypertension medications.
Do not initiate GAVRETO in patients with uncontrolled hypertension. Optimize blood pressure prior to initiating GAVRETO. Monitor blood pressure after 1 week, at least monthly thereafter and as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue GAVRETO based on the severity [see Dosage and Administration (2.3)] .
5.3 Hepatoxicity
5.4 Hepatotoxicity
Serious hepatic adverse reactions occurred in 1.5% of patients treated with GAVRETO. Increased AST occurred in 49% of patients, including Grade 3 or 4 in 7% and increased ALT occurred in 37% of patients, including Grade 3 or 4 in 4.8% [see Adverse Reactions (6.1)]. The median time to first onset for increased AST was 15 days (range: 5 days to 2.5 years) and for increased ALT was 24 days (range: 7 days to 3.7 years).
Monitor AST and ALT prior to initiating GAVRETO, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated. Withhold, reduce dose or permanently discontinue GAVRETO based on severity [see Dosage and Administration (2.3)] .
5.45 Hemorrhagic Events
Serious, including fatal, hemorrhagic events can occur with GAVRETO. Grade ≥ 3 hemorrhagic events occurred in 4.1% of patients treated with GAVRETO including one patient with a fatal hemorrhagic event.
Permanently discontinue GAVRETO in patients with severe or life-threatening hemorrhage [see Dosage and Administration (2.3)].
5.56 Tumor Lysis Syndrome
Cases of tumor lysis syndrome (TLS) have been reported in patients with medullary thyroid carcinoma receiving GAVRETO [see Adverse Reactions (6.1)] . Patients may be at risk of TLS if they have rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration. Closely monitor patients at risk, consider appropriate prophylaxis including hydration, and treat as clinically indicated.
5.67 Risk of Impaired Wound Healing
Impaired wound healing can occur in patients who receive drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. Therefore, GAVRETO has the potential to adversely affect wound healing.
Withhold GAVRETO for at least 5 days prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of GAVRETO after resolution of wound healing complications has not been established.
5.78 Embryo-Fetal Toxicity
Based on findings from animal studies and its mechanism of action, GAVRETO can cause fetal harm when administered to a pregnant woman. Oral administration of pralsetinib to pregnant rats during the period of organogenesis resulted in malformations and embryolethality at maternal exposures below the human exposure at the clinical dose of 400 mg once daily.
Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with GAVRETO and for 2 weeks after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with GAVRETO and for 1 week after the last dose [see Use in Specific Populations (8.1, 8.3)] .

Adverse reactions

Changed179 words added, 46 removed
1 unchanged line
The following clinically significant adverse reactions are described elsewhere in the labeling:
Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5.1)]
Serious Infections, Including Opportunistic Infections [see Warnings and Precautions (5.1)]
Hypertension [see Warnings and Precautions (5.2)]
Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5.2)]
HepatotoxicityHypertension [see Warnings and Precautions (5.3)]
Hemorrhagic EventsHepatotoxicity [see Warnings and Precautions (5.4)]
Tumor LysisHemorrhagic SyndromeEvents [see Warnings and Precautions (5.5)]
Risk of Impaired Wound Healing [see Warnings and Precautions (5.6)]
Tumor Lysis Syndrome [see Warnings and Precautions (5.6)]
Embryo-Fetal Toxicity [see Warnings and Precautions (5.7)]
Risk of Impaired Wound Healing [see Warnings and Precautions (5.7)]
Embryo-Fetal Toxicity [see Warnings and Precautions (5.8)]
6.1 Clinical Trials Experience
1 unchanged line
The pooled safety population in the WARNINGS AND PRECAUTIONS reflect exposure to GAVRETO as a single agent at 400 mg orally once daily in 540 patients in ARROW [see Clinical Studies (14)]. Among 540 patients who received GAVRETO, 71% were exposed for 6 months or longer and 57% were exposed for greater than one year. The most common adverse reactions (≥ 25%) were musculoskeletal pain, constipation, hypertension, diarrhea, fatigue, edema, pyrexia, and cough. The most common Grade 3-4 laboratory abnormalities (≥ 2%) were decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased phosphate, decreased leukocytes, decreased sodium, increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), decreased calcium (corrected), decreased platelets, increased alkaline phosphatase, increased potassium, decreased potassium and increased bilirubin.
In addition to the 540 patients, certain subsections in the WARNINGS AND PRECAUTIONS describe adverse reactions observed with exposure to GAVRETO as a single agent in a randomized, open-label study, AcceleRET-Lung (NCT04222972), which enrolled 223 patients with RET-fusion positive locally advanced unresectable or metastatic NSCLC.
RETFusionRET Fusion-Positive Non-Small Cell Lung Cancer
The safety of GAVRETO was evaluated as a single agent at 400 mg orally once daily in 281 patients with metastatic rearranged during transfection (RET RETfusionfusion-positive) non-small cell lung cancer (NSCLC) in ARROW [see Clinical Studies (14.1)]. Among the 281 patients who received GAVRETO, 72% were exposed for 6 months or longer and 56% were exposed for ≥1 year.
The median age was 60 years (range: 26 to 87 years); 54% were female, 46% were White, 46% were Asian, and 4% were Hispanic/Latino.
60 unchanged lines
RET-altered Thyroid Cancer
The safety of GAVRETO was evaluated as a single agent at 400 mg orally once daily in 138 patients with RET-altered Thyroid Cancer (including 19 patients with RETfusionRET fusion-positive thyroid cancer) in ARROW [see Clinical Studies (14.2)]. Among the 138 patients who received GAVRETO, 68% were exposed for 6 months or longer, and 40% were exposed for greater than one year.
The median age was 59 years (range: 18 to 83 years); 36% were female, 74% were White, 17% were Asian, and 6% were Hispanic/Latino.
58 unchanged lines
Clinically relevant laboratory abnormalities in patients who received GAVRETO included increased phosphate (40%).
Other Clinical Trials Experience
AcceleRET-Lung trial (NCT04222972)
In AcceleRET-Lung trial (NCT04222972), single agent GAVRETO (n=108) was compared to chemotherapy/immunotherapy (n=104) in patients with RET fusion-positive NSCLC. Adverse reactions were infections (72% vs.52%), including pneumonia (29% vs. 6%), urinary tract infection (22% vs. 8%), and opportunistic infections (20% vs. 6%). Opportunistic infections included pneumocystis jirovecii pneumonia, fungal infections, legionella pneumonia, cytomegalovirus infection, and herpes simplex.

Drug interactions

Changedpunctuation or symbols only
4 unchanged lines
Strong or Moderate CYP3A Inducers
Concomitant use with a strong CYP3A inducer decreases pralsetinib exposure [see Clinical Pharmacology (12.3)] , which may decrease efficacy of GAVRETO. Avoid concomitant use of GAVRETO with strong or moderate CYP3A inducers. If coadministration of GAVRETO with strong or moderate CYP3A inducers cannot be avoided, increase the GAVRETO dose [see Dosage and Administration (2.5)].

Use in specific populations

Changed8 words added, 4 removed
23 unchanged lines
8.4 Pediatric Use
The safety and effectiveness of GAVRETO have been established in pediatric patients aged 12 years and older for RETfusionRET fusion-positive thyroid cancer. Use of GAVRETO in this age group is supported by evidence from an adequate and well-controlled study of GAVRETO in adults with additional population pharmacokinetic data demonstrating that age and body weight had no clinically meaningful effect on the pharmacokinetics of pralsetinib, that the exposure of pralsetinib is expected to be similar between adults and pediatric patients age 12 years and older, and that the course of RETfusionRET fusion-positive thyroid cancer is sufficiently similar in adults and pediatric patients to allow extrapolation of data in adults to pediatric patients [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.2)].
The safety and effectiveness of GAVRETO have not been established in pediatric patients with RETfusionRET fusion-positive NSCLC or in pediatric patients younger than 12 years old with RETfusionRET fusion-positive thyroid cancer.
Animal Toxicity Data
7 unchanged lines

Clinical pharmacology

Changed57 words added, 49 removed
1 unchanged line
12.1 Mechanism of Action
Pralsetinib is a kinase inhibitor of wild-type RETandRET and oncogenic RETfusionsRET fusions (CCDC6- RET) and mutations (RET RETV804LV804L, RETV804MRET V804M and RETM918TRET M918T) with half maximal inhibitory concentrations (IC 50sIC50s) less than 0.5 nM. In purified enzyme assays, pralsetinib inhibited DDR1, TRKC, FLT3, JAK1-2, TRKA, VEGFR2, PDGFRB, and FGFR1 at higher concentrations that were still clinically achievable at C maxCmax. In cellular assays, pralsetinib inhibited RETatRET at approximately 14-, 40-, and 12-fold lower concentrations than VEGFR2, FGFR2, and JAK2, respectively.
Certain RETfusionRET fusion proteins and activating point mutations can drive tumorigenic potential through hyperactivation of downstream signaling pathways leading to uncontrolled cell proliferation. Pralsetinib exhibited anti-tumor activity in cultured cells and animal tumor implantation models harboring oncogenic RETfusionsRET fusions or mutations including KIF5B- RET, CCDC6- RET, RETM918TRET M918T, RETC634WRET C634W, RETV804ERET V804E, RETV804LRET V804L and RETV804MRET V804M. In addition, pralsetinib prolonged survival in mice implanted intracranially with tumor models expressing KIF5B-RET REToror CCDC6- RET.
12.2 Pharmacodynamics
3 unchanged lines
12.3 Pharmacokinetics
At 400 mg GAVRETO once daily under fasting conditions, the steady state mean [% coefficient of variation (CV%)] of maximum observed plasma concentration (C maxCmax) and area under the concentration-time curve (AUC 0AUC0-24h) of pralsetinib was 2,470 (55%) ng/mL and 36,700 (66%) h•ng/mL, respectively. Pralsetinib CCmax maxandand AUC increased inconsistently over the dose range of 60 mg to 600 mg once daily (0.15 to 1.5 times the recommended dose). Pralsetinib plasma concentrations reached steady state by 3 to 5 days. The mean accumulation ratio was approximately 2-fold after once-daily oral administration.
Absorption
The median time to peak concentration (T maxTmax) ranged from 2 to 4 hours following single doses of pralsetinib 60 mg to 600 mg.
Food Effect
Following administration of a single dose of 200 mg with a high-fat meal, (approximately 800 to 1000 calories with 50 to 60% of calories from fat), the mean CCmax maxofof pralsetinib was increased by 2.0-fold, the mean AUC 0AUC0-INFwasINF was increased by 2.2-fold, and the median TTmax maxwaswas delayed from 4 to 8.5 hours, compared to the fasted state.
Distribution
1 unchanged line
Elimination
The mean (±standard deviation) plasma elimination half-life (T ½T½) of pralsetinib is 16 hours (10) following single doses and 20 hours (12) following multiple doses of pralsetinib. The mean (CV%) apparent oral clearance (CL/F) of pralsetinib is 11 L/h (66%) at steady state.
Metabolism
1 unchanged line
Excretion
Approximately 73% (66% as unchanged) of the total administered radioactive dose [ 14C] pralsetinib was recovered in feces and 6% (4.8% as unchanged) was recovered in urine.
Specific Populations
2 unchanged lines
Clinical Studies and Model-Informed Approach
CYP3A Inhibitors: Coadministration of multiple doses of CYP3A inhibitors increases pralsetinib CCmax maxandand AUC.
Table 9: Observed or Predicted Increase in Pralsetinib Exposure after Coadministration of CYP3A Inhibitors
6 unchanged lines
Moderate CYP3A Inhibitors | Fluconazole (400 mg once daily) | 1.2-fold | 1.7-fold
P-gp Inhibitors: Coadministration of cyclosporine (single 600 mg dose) with a single 200 mg dose of pralsetinib in healthy subjects increased pralsetinib AUC 0AUC0-infbyinf by 1.8-fold and CCmax maxbyby 1.5-fold, relative to a 200 mg dose of pralsetinib administered alone.
Strong CYP3A Inducers: Coadministration of rifampin 600 mg once daily with a single GAVRETO 400 mg dose decreased pralsetinib AUC 0AUC0-INFbyINF by 68% and CCmax maxbyby 30%.
Moderate CYP3A Inducers: Coadministration of multiple doses of efavirenz (600 mg once daily) is predicted to decrease the pralsetinib AUC by 45% and CCmax maxbyby 18% .
Mild CYP3A Inducers: No clinically significant differences in the PK of pralsetinib were identified when GAVRETO was coadministered with mild CYP3A inducers.
Acid-Reducing Agents: No clinically significant differences in the PK of pralsetinib were observed when GAVRETO was coadministered with gastric acid reducing agents.
In Vitro Studies
1 unchanged line
Pralsetinib is an inducer of CYP2C8, CYP2C9, and CYP3A, but not an inducer of CYP1A2, CYP2B6, or CYP2C19 at clinically relevant concentrations.
Transporter Systems: Pralsetinib is a substrate of P-gp and BCRP, but not a substrate of BSEP, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, MATE2-K, OAT1, or OAT3.
Pralsetinib is an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, MATE2-K, and BSEP, but not an inhibitor of OCT1, OCT2, and OAT1A3 at clinically relevant concentrations.

Clinical studies

Changed37 words added, 19 removed
14 CLINICAL STUDIES
14.1 Metastatic RETFusionRET Fusion-Positive Non-Small Cell Lung Cancer
The efficacy of GAVRETO was evaluated in patients with RETfusionRET fusion-positive metastatic NSCLC in a multicenter, non-randomized, open-label, multi-cohort clinical trial (ARROW, NCT03037385). The study enrolled, in separate cohorts, patients with metastatic RETfusionRET fusion-positive NSCLC who had progressed on platinum-based chemotherapy and treatment-naïve patients with metastatic NSCLC. Identification of a RETgeneRET gene fusion was determined by local laboratories using next generation sequencing (NGS), fluorescence in situ hybridization (FISH), and other tests. Among the 237 patients in the efficacy population(s) described in this section, samples from 40% of patients were retrospectively tested with the LIFE Technologies Corporation Oncomine Dx Target Test (ODxTT). Patients with asymptomatic central nervous system (CNS) metastases, including patients with stable or decreasing steroid use within 2 weeks prior to study entry, were enrolled. Patients received GAVRETO 400 mg orally once daily until disease progression or unacceptable toxicity.
The major efficacy outcome measures were overall response rate (ORR) and duration of response (DOR), as assessed by a blinded independent central review (BICR) according to RECIST v1.1.
Metastatic RETFusionRET Fusion-Positive NSCLC Previously Treated with Platinum Chemotherapy
Efficacy was evaluated in 130 patients with RETfusionRET fusion-positive NSCLC with measurable disease who were previously treated with platinum chemotherapy enrolled into a cohort of ARROW.
The median age was 59 years (range: 26 to 85); 51% were female, 40% were White, 50% were Asian, 4.6% were Hispanic/Latino. ECOG performance status was 0-1 (95%) or 2 (3.8%), 99% of patients had metastatic disease, and 41% had either a history of or current CNS metastasis. Patients received a median of 2 prior systemic therapies (range 1–6); 42% had prior anti-PD-1/PD-L1 therapy and 27% had prior kinase inhibitors. A total of 48% of the patients received prior radiation therapy. RETfusionsRET fusions were detected in 80% of patients using NGS (37% tumor samples; 15% blood or plasma samples, 28% unknown), 13% using FISH, and 2% using other methods. The most common RETfusionRET fusion partners were KIF5B (70%) and CCDC6 (19%).
Efficacy results for RETfusionRET fusion-positive NSCLC patients who received prior platinum-based chemotherapy are summarized in Table 10.
Table 10: Efficacy Results in ARROW (Metastatic RET Fusion-Positive NSCLC Previously Treated with Platinum Chemotherapy)
8 unchanged lines
For the 54 patients who received an anti-PD-1 or anti-PD-L1 therapy, either sequentially or concurrently with platinum-based chemotherapy, an exploratory subgroup analysis of ORR was 59% (95% CI: 45, 72) and the median DOR was 22.3 months (95% CI: 8.0, NE).
Among the 130 patients with RET-fusion fusion-positive NSCLC, 10 had measurable CNS metastases at baseline as assessed by BICR. No patients received radiation therapy (RT) to the brain within 2 months prior to study entry. Responses in intracranial lesions were observed in 7 of these 10 patients including 2 patients with a CNS complete response; 71% of responders had a DOR of ≥ 6 months.
Treatment-naïve RETFusionRET Fusion-Positive NSCLC
Efficacy was evaluated in 107 patients with treatment-naïve RETfusionRET fusion-positive NSCLC with measurable disease enrolled into ARROW.
The median age was 62 years (range 30 to 87); 53% were female, 49% were White, 45% were Asian, and 2.8% were Hispanic or Latino. ECOG performance status was 0-1 for 99% of the patients and 98% of patients had metastatic disease; 28% had either history of or current CNS metastasis. RETfusionsRET fusions were detected in 68% of patients using NGS (30% tumor samples; 17% blood or plasma; 22% unknown) and 19% using FISH. The most common RETfusionRET fusion partners were KIF5B (71%) and CCDC6 (18%).
Efficacy results for treatment-naïve RETfusionRET fusion-positive NSCLC are summarized in Table 11.
Table 11: Efficacy Results for ARROW (Treatment-Naïve Metastatic RET Fusion-Positive NSCLC)
6 unchanged lines
Patients with DOR ≥ 12-months , % | 45
14.2 RETFusionRET Fusion-Positive Thyroid Cancer
The efficacy of GAVRETO was evaluated in RETfusionRET fusion-positive metastatic thyroid cancer patients in a multicenter, open-label, multi-cohort clinical trial (ARROW, NCT03037385). All patients with RETfusionRET fusion-positive thyroid cancer were required to have disease progression following standard therapy, measurable disease by RECIST version 1.1, and have RETfusionRET fusion status as detected by local testing (89% NGS tumor samples and 11% using FISH).
The median age was 61 years (range: 46 to 74); 67% were male, 78% were White, 22% were Asian, 11% were Hispanic/Latino. All patients (100%) had papillary thyroid cancer. ECOG performance status was 0-1 (100%), all patients (100%) had metastatic disease, and 56% had a history of CNS metastases. Patients had received a median of 2 prior therapies (range 1-8). Prior systemic treatments included prior radioactive iodine (100%) and prior sorafenib and/or lenvatinib (56%).
10 unchanged lines

Patient counseling information

Changed47 words added, 11 removed
17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (PatientMedication InformationGuide).
Serious Infections, Including Opportunistic Infections
Advise patients that GAVRETO may increase the risk of serious infections and to contact their healthcare provider if they experience symptoms of infections [see Warnings and Precautions (5.1)].
ILD/Pneumonitis
Advise patients to contact their healthcare provider if they experience new or worsening respiratory symptoms [see Warnings and Precautions (5.12)].
Hypertension
Advise patients that they will require regular blood pressure monitoring and to contact their healthcare provider if they experience symptoms of increased blood pressure or elevated readings [see Warnings and Precautions (5.23)].
Hepatotoxicity
Advise patients that hepatotoxicity can occur and to immediately contact their healthcare provider for signs or symptoms of hepatotoxicity [see Warnings and Precautions (5.34)].
Hemorrhagic Events
Advise patients that GAVRETO may increase the risk for bleeding and to contact their healthcare provider if they experience any signs or symptoms of bleeding [see Warnings and Precautions (5.45)].
Tumor Lysis Syndrome
Advise patients to contact their healthcare provider promptly to report any signs and symptoms of TLS [see Warnings and Precautions (5.56)].
Risk of Impaired Wound Healing
Advise patients that GAVRETO may impair wound healing. Advise patients that temporary interruption of GAVRETO is recommended prior to any elective surgery [see Warnings and Precautions (5.67)].
Embryo-Fetal Toxicity
Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.78), Use in Specific Populations (8.1)].
Advise females of reproductive potential to use effective non-hormonal contraception during the treatment with GAVRETO and for 2 weeks after the last dose [see Use in Specific Populations (8.3)].
5 unchanged lines
Drug Interactions
AdvisepatientsAdvise patients and caregivers to inform their healthcare provider of all concomitant medications, includingprescriptionincluding prescription medicines, over-the-counter drugs, vitamins, and herbal products [see Drug Interactions (7.1)].
Administration
1 unchanged line

Medication guide

New section1,517 words added
This Medication Guide has been approved by the U.S. Food and Drug Administration. | Revised: 12/2025
MEDICATION GUIDE GAVRETO (gav-REH-toh) (pralsetinib) capsules, for oral use
What is the most important information I should know about GAVRETO? GAVRETO may cause serious side effects, including:
Serious infections. GAVRETO may increase your risk for serious infections, including infections caused by bacteria, fungi, or viruses, or infections that can happen when your immune system is weak (opportunistic infections). These serious infections can lead to hospitalization or death. Tell your healthcare provider right away if you get symptoms of an infection, including:
| chills body aches fever confusion | nausea vomiting stomach pain weakness | diarrhea cough or shortness of breath burning or pain when you urinate skin rash
See "What are the possible side effects of GAVRETO?" for more information about side effects.
What is GAVRETO?
GAVRETO is a prescription medicine used to treat certain cancers caused by abnormal rearranged during transfection (RET) genes in: adults with non-small cell lung cancer (NSCLC) that has spread. adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread who require a medicine by mouth or injection (systemic therapy) and who have received radioactive iodine and it did not work or is no longer working.
Your healthcare provider will perform a test to make sure that GAVRETO is right for you.
It is not known if GAVRETO is safe and effective when used to treat cancers caused by abnormal RET genes: in children for the treatment of NSCLC or in children younger than 12 years of age for the treatment of thyroid cancer.
Before taking GAVRETO, tell your healthcare provider about all of your medical conditions, including if you: have an infection. See "What is the most important information I should know about GAVRETO?" have lung or breathing problems other than lung cancer have high blood pressure have bleeding problems have liver problems plan to have surgery. You should stop taking GAVRETO at least 5 days before your planned surgery. See "What are the possible side effects of GAVRETO?" are pregnant or plan to become pregnant. GAVRETO can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider will do a pregnancy test before you start treatment with GAVRETO. You should use an effective form of non-hormonal birth control (contraception) during treatment and for 2 weeks after your last dose of GAVRETO. Birth control methods that contain hormones (such as birth control pills, injections or transdermal system patches) may not work as well during treatment with GAVRETO. Talk to your healthcare provider about birth control methods that may be right for you during this time. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with GAVRETO. Males with female partners who are able to become pregnant: You should use effective birth control (contraception) during treatment and for 1 week after your last dose of GAVRETO. are breastfeeding or plan to breastfeed. It is not known if GAVRETO passes into your breast milk. Do not breastfeed during treatment and for 1 week after your last dose of GAVRETO.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking GAVRETO with other medicines may affect how GAVRETO works.
How should I take GAVRETO? Take GAVRETO exactly as your healthcare provider tells you to take it. Take your prescribed dose of GAVRETO 1 time each day. Take GAVRETO on an empty stomach. Do not eat for at least 2 hours before and at least 1 hour after taking GAVRETO. Do not change your dose or stop taking GAVRETO unless your healthcare provider tells you to. Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with GAVRETO if you develop side effects. If you miss a dose of GAVRETO, take it as soon as possible on the same day. Then take your next dose of GAVRETO at your regular time the next day. If you vomit after taking a dose of GAVRETO, do not take an extra dose. Take your next dose of GAVRETO at your regular time the next day.
What are the possible side effects of GAVRETO?
GAVRETO may cause serious side effects, including: See "What is the most important information I should know about GAVRETO?" Lung problems. GAVRETO may cause severe or life-threatening inflammation of the lungs during treatment, that can lead to death. Tell your healthcare provider right away if you have any new or worsening symptoms, including:
| shortness of breath | cough | fever
High blood pressure (hypertension). High blood pressure is common with GAVRETO and may sometimes be severe. You should check your blood pressure regularly during treatment with GAVRETO. Tell your healthcare provider if you have increased blood pressure readings or get any symptoms of high blood pressure, including:
| confusion headaches shortness of breath | dizziness chest pain
Liver problems. Liver problems (increased liver function blood test results) can happen during treatment with GAVRETO and may sometimes be serious. Your healthcare provider will do blood tests before and during treatment with GAVRETO to check you for liver problems. Tell your healthcare provider right away if you get any signs or symptoms of liver problem during treatment, including:
| yellowing of your skin or the white part of your eyes (jaundice) dark "tea-colored" urine sleepiness bleeding or bruising | loss of appetite nausea or vomiting pain on the upper right side of your stomach area
Bleeding problems. GAVRETO can cause bleeding which can be serious and cause death. Tell your healthcare provider if you have any signs or symptoms of bleeding during treatment, including:
| vomiting blood or if your vomit looks like coffee grounds pink or brown urine red or black (looks like tar) stools coughing up blood or blood clots unusual bleeding or bruising of your skin menstrual bleeding that is heavier than normal | unusual vaginal bleeding nose bleeds that happen often drowsiness or difficulty being awakened confusion headache change in speech
Tumor lysis syndrome (TLS). TLS is caused by a fast breakdown of cancer cells. TLS can cause you to have kidney failure and the need for dialysis treatment, an abnormal heartbeat, and may sometimes lead to hospitalization. Your healthcare provider may do blood tests to check you for TLS. You should stay well hydrated during treatment with GAVRETO. Call your healthcare provider or get emergency medical help right away if you develop any of these symptoms during treatment with GAVRETO:
| nausea vomiting weakness swelling | shortness of breath muscle cramps seizures
Risk of wound healing problems. Wounds may not heal properly during treatment with GAVRETO. Tell your healthcare provider if you plan to have any surgery before or during treatment with GAVRETO. You should not take GAVRETO for at least 5 days before surgery. Your healthcare provider should tell you when you may start taking GAVRETO again after surgery.
The most common side effects of GAVRETO include:
muscle and joint pain constipation diarrhea tiredness | swelling of your face, arms, legs, hands, and feet (edema) fever cough
The most common severe abnormal blood test results with GAVRETO include: decreased white blood cell, red blood cell, and platelet counts decreased levels of phosphate, body salt (sodium), calcium and potassium in the blood abnormal liver function blood tests increased levels of enzyme called alkaline phosphatase in the blood (test for liver or bone problems) increased levels of potassium in the blood GAVRETO may affect fertility in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.
These are not all the possible side effects of GAVRETO.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store GAVRETO? Store GAVRETO at room temperature between 68°F to 77°F (20°C to 25°C). Protect GAVRETO from moisture.
Keep GAVRETO and all medicines out of the reach of children.
General information about the safe and effective use of GAVRETO.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use GAVRETO for a condition for which it was not prescribed. Do not give GAVRETO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about GAVRETO that is written for health professionals.
What are the ingredients in GAVRETO?
Active ingredient: pralsetinib
Inactive ingredients: citric acid, hydroxypropyl methylcellulose (HPMC), magnesium stearate, microcrystalline cellulose (MCC), pregelatinized starch and sodium bicarbonate.
Capsule shell: FD&C Blue #1 (Brilliant Blue FCF), hypromellose and titanium dioxide.
White printing ink: butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, strong ammonia solution and titanium dioxide.
Manufactured for: Rigel Pharmaceuticals, Inc., South San Francisco, CA 94080 GAVRETO® is a registered trademark of Rigel Pharmaceuticals, Inc. For more information, go to www.GAVRETO.com or call 1-800-983-1329.

Patient information

Removed1,371 removed
This Patient Information has been approved by the U.S. Food and Drug Administration. | Revised: 06/2024
PATIENT INFORMATION GAVRETO ®(gav-REH-toh) (pralsetinib) capsules
What is GAVRETO?
GAVRETO is a prescription medicine used to treat certain cancers caused by abnormal rearranged during transfection (RET) genes in: adults with non-small cell lung cancer (NSCLC) that has spread. adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread who require a medicine by mouth or injection (systemic therapy) and who have received radioactive iodine and it did not work or is no longer working.
Your healthcare provider will perform a test to make sure that GAVRETO is right for you.
It is not known if GAVRETO is safe and effective when used to treat cancers caused by abnormal RET genes: in children for the treatment of NSCLC or in children younger than 12 years of age for the treatment of thyroid cancer.
Before taking GAVRETO, tell your healthcare provider about all of your medical conditions, including if you: have lung or breathing problems other than lung cancer have high blood pressure have bleeding problems have liver problems plan to have surgery. You should stop taking GAVRETO at least 5 days before your planned surgery. See " What are the possible side effects of GAVRETO?" are pregnant or plan to become pregnant. GAVRETO can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider will do a pregnancy test before you start treatment with GAVRETO. You should use an effective form of non-hormonal birth control (contraception) during treatment and for 2 weeksafter your last dose of GAVRETO. Birth control methods that contain hormones (such as birth control pills, injections or transdermal system patches) may not work as well during treatment with GAVRETO. Talk to your healthcare provider about birth control methods that may be right for you during this time. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with GAVRETO. Males with female partners who are able to become pregnant: You should use effective birth control (contraception) during treatment and for 1 weekafter your last dose of GAVRETO. are breastfeeding or plan to breastfeed. It is not known if GAVRETO passes into your breast milk. Do not breastfeed during treatment and for 1 weekafter your last dose of GAVRETO.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking GAVRETO with other medicines may affect how GAVRETO works.
How should I take GAVRETO? Take GAVRETO exactly as your healthcare provider tells you to take it. Take your prescribed dose of GAVRETO 1 time each day. Take GAVRETO on an empty stomach. Do noteat for at least 2 hours before and at least 1 hour after taking GAVRETO. Do notchange your dose or stop taking GAVRETO unless your healthcare provider tells you to. Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with GAVRETO if you develop side effects. If you miss a dose of GAVRETO, take it as soon as possible on the same day. Then take your next dose of GAVRETO at your regular time the next day. If you vomit after taking a dose of GAVRETO, do not take an extra dose. Take your next dose of GAVRETO at your regular time the next day.
What are the possible side effects of GAVRETO?
GAVRETO may cause serious side effects, including: Lung problems.GAVRETO may cause severe or life-threatening inflammation of the lungs during treatment, that can lead to death. Tell your healthcare provider right away if you have any new or worsening symptoms, including:
| shortness of breath | cough | fever
High blood pressure (hypertension).High blood pressure is common with GAVRETO and may sometimes be severe. You should check your blood pressure regularly during treatment with GAVRETO. Tell your healthcare provider if you have increased blood pressure readings or get any symptoms of high blood pressure, including:
| confusion headaches shortness of breath | dizziness chest pain
Liver problems.Liver problems (increased liver function blood test results) can happen during treatment with GAVRETO and may sometimes be serious. Your healthcare provider will do blood tests before and during treatment with GAVRETO to check you for liver problems. Tell your healthcare provider right away if you get any signs or symptoms of liver problem during treatment, including:
| yellowing of your skin or the white part of your eyes (jaundice) dark "tea-colored" urine sleepiness bleeding or bruising | loss of appetite nausea or vomiting pain on the upper right side of your stomach area
Bleeding problems.GAVRETO can cause bleeding which can be serious and cause death. Tell your healthcare provider if you have any signs or symptoms of bleeding during treatment, including:
| vomiting blood or if your vomit looks like coffee grounds pink or brown urine red or black (looks like tar) stools coughing up blood or blood clots unusual bleeding or bruising of your skin menstrual bleeding that is heavier than normal | unusual vaginal bleeding nose bleeds that happen often drowsiness or difficulty being awakened confusion headache change in speech
Tumor lysis syndrome (TLS).TLS is caused by a fast breakdown of cancer cells. TLS can cause you to have kidney failure and the need for dialysis treatment, an abnormal heartbeat, and may sometimes lead to hospitalization. Your healthcare provider may do blood tests to check you for TLS. You should stay well hydrated during treatment with GAVRETO. Call your healthcare provider or get emergency medical help right away if you develop any of these symptoms during treatment with GAVRETO:
| nausea vomiting weakness swelling | shortness of breath muscle cramps seizures
Risk of wound healing problems.Wounds may not heal properly during treatment with GAVRETO. Tell your healthcare provider if you plan to have any surgery before or during treatment with GAVRETO. You should not take GAVRETO for at least 5 days before surgery. Your healthcare provider should tell you when you may start taking GAVRETO again after surgery.
The most common side effects of GAVRETO include:
muscle and joint pain constipation diarrhea tiredness | swelling of your face, arms, legs, hands, and feet (edema) fever cough
The most common severe abnormal blood test results with GAVRETO include: decreased white blood cell, red blood cell, and platelet counts decreased levels of phosphate, body salt (sodium), calcium and potassium in the blood abnormal liver function blood tests increased levels of enzyme called alkaline phosphatase in the blood (test for liver or bone problems) increased levels of potassium in the blood GAVRETO may affect fertility in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.
These are not all the possible side effects of GAVRETO.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store GAVRETO? Store GAVRETO at room temperature between 68°F to 77°F (20°C to 25°C). Protect GAVRETO from moisture.
Keep GAVRETO and all medicines out of the reach of children.
General information about the safe and effective use of GAVRETO.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use GAVRETO for a condition for which it was not prescribed. Do not give GAVRETO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about GAVRETO that is written for health professionals.
What are the ingredients in GAVRETO?
Active ingredient:pralsetinib
Inactive ingredients:citric acid, hydroxypropyl methylcellulose (HPMC), magnesium stearate, microcrystalline cellulose (MCC), pregelatinized starch and sodium bicarbonate.
Capsule shell: FD&C Blue #1 (Brilliant Blue FCF), hypromellose and titanium dioxide.
White printing ink: butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, strong ammonia solution and titanium dioxide.
Manufactured for: Rigel Pharmaceuticals, Inc., South San Francisco, CA 94080 GAVRETO® is a registered trademark of Rigel Pharmaceuticals, Inc. For more information, go to www.GAVRETO.com or call 1-800-983-1329.

Untitled section

Changed10 words added, 8 removed
GAVRETO ® [pralsetinib]
Manufactured for:
Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. South San Francisco, CA 94080
South San Francisco, CA 94080
GAVRETO® is a registered trademark of Rigel Pharmaceuticals, Inc.
For more information go to www.GAVRETO.com or call 1-800-983-1329.
12/2025

Unchanged: Dosage forms and strengths, Contraindications, Description, Nonclinical toxicology, How supplied, PRINCIPAL DISPLAY PANEL - 60 Capsule - Carton, PRINCIPAL DISPLAY PANEL - 90 Capsule - Carton.

Every version

5 versions of set 16edd46e-28b8-f06d-e063-6394a90ae31b, newest first.
VersionPublished on DailyMedCompareSPL file
8Jan 28, 2026Shown belowDownload .zip
7Dec 19, 2025With version 6Download .zip
6Jun 24, 2024With version 4Download .zip
4Jun 12, 2024With version 1Download .zip
1May 9, 2024First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.